Jul 08, 2019 PRESS RELEASES Comments Off on Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025
LONDON, July 08, 2019 (GLOBE NEWSWIRE) — Today, the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca announced the Lung Ambition Alliance, a new partnership with a bold ambition to eliminate lung cancer as a cause of death. The first goal of the Alliance will be to double five-year survival for patients with lung cancer by 2025.
Every 18 seconds, a life is lost to lung cancer.1 In 2018 alone, approximately 1.8 million people died from the disease.1 Forty percent of patients are diagnosed when the cancer has already spread beyond the lung and their prognosis has worsened.2 Currently, only one in five lung cancer patients are alive five years after diagnosis.3
Jesme Fox, Secretary for GLCC, said: “The Lung Ambition Alliance has been created at a pivotal time for lung cancer. Scientific advances are enabling new possibilities to transform diagnosis, treatment and the management of the disease. Yet barriers remain to improving and accelerating care. As members of the lung cancer community, we have a responsibility to come together with urgency to advocate for and advance the best solutions for patients.”
The Alliance represents a broad range of complementary expertise, including research and education (IASLC), diagnostics (Guardant Health), patient advocacy (GLCC), and medicines research and development (AstraZeneca).
The founding partners have identified three priorities: increasing screening and early diagnosis, delivering innovative medicine and improving the quality of care for people with lung cancer. Initial projects being accelerated through the Alliance include:
Giorgio Scagliotti, President of IASLC said: “Effective screening is key to finding and diagnosing lung cancer and other thoracic malignancies early, which can translate to more options and longer survival. Yet screening is underutilized around the world for several reasons. The application of quantitative imaging approaches like ELIC could improve the accuracy and the efficiency of lung cancer screening. Our platform is poised to become an important global resource for lung cancer researchers and care teams looking to expand their knowledge. The Lung Ambition Alliance is providing the focus, expertise, and resources needed to dramatically accelerate the expansion of our data catalogue.”
AmirAli Talasaz, President and Chief Operating Officer, Guardant Health said: “Precision medicine is improving prognosis for some lung cancer patients and delivering better clinical outcomes. We believe precision medicine approaches can be even more effective when utilized earlier in the course of the disease, or immediately upon detection of relapse. The Major Pathologic Response Project will help accelerate development of potentially curative treatment options, with the identification of surrogate endpoints that can be used to quicken clinical trials and novel diagnostic approaches – like the detection of circulating tumor DNA in blood samples – to identify patients with a poor prognosis, allow routine assessment of therapeutic response, and promote ongoing monitoring of cancer remission.”
Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, AstraZeneca, said: “Lung cancer is a highly personal disease, and care approaches can vary widely around the world. In order to reach our survival goal, we must encourage initiatives that address barriers at the country level and increase screening and early diagnosis, aid the development of innovative medicine and improve quality care. By joining together with partners who have broad global networks and distinct but complementary areas of focus in lung cancer, we are better positioned to address issues those patients face.”
The Alliance will sponsor an international survey, led by Ipsos MORI, to identify local barriers that need priority focus. Results, expected in the fall of 2019, will be used to further refine and shape the priorities of the Lung Ambition Alliance. Information about the survey, and how the community can share their perspectives, can be found at LungAmbitionAlliance.org.
About the Lung Ambition Alliance
The Lung Ambition Alliance is a flagship partnership of diverse organizations united in the quest to eliminate lung cancer as a cause of death. The Alliance aims to accelerate progress and bring meaningful change for lung cancer patients by amplifying the expertise of each partner and prioritizing meaningful projects with potential to further its goal. The founding partners – the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca – will explore and overcome barriers to screening and early diagnosis, the development of innovative medicine and quality care, and pursue an ambitious vision for the future in lung cancer that starts with doubling five-year survival by 2025.
For more information, visit www.lungambitionalliance.org.
About the Founding Partners
Accelerating Advances for People with Lung Cancer.
1 World Health Organization. International Agency for Research on Cancer. Fact Sheet – Lung Cancer. Available at http://gco.iarc.fr/today/data/
2 EpiCast Report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016.
3 Cancer.Net. Lung Cancer – Non-Small Cell – Statistics. Available at www.cancer.net/cancer-types/
4 IASLC. IASLC Successfully Pilots Early Lung Imaging Confederation Project. Available at https://www.iaslc.org/news/
5 IASLC. IASLC Pathology Committee. Available at https://www.iaslc.org/
Comments Off on Agricultural losses from heavy rains hit NT$7 million
Comments Off on Taiwan’s Air Force says it plans to add new wing of F16V
Comments Off on Taiwan raises 2019 GDP growth forecast
Comments Off on Sundance Energy Australia Limited Reports Second Quarter 2019 Financial and Operational Results
Comments Off on Constellation Brands to Present at the Barclays Global Consumer Staples Conference on September 4, 2019
Comments Off on Stevie® Awards Announce Winners in 16th Annual International Business Awards® from Across the Globe